PRME

3.5657.16%
AL

Ann L. Lee

Chief Technical Officer

Dr. Ann L. Lee, Ph.D, serves as Chief Technical Officer at Prime Medicine, Inc. since October 2021, where she is responsible for analytical development, supply chain, quality and manufacturing operations. Dr. Lee has been an Independent Director at Coya Therapeutics, Inc. since June 1, 2021. He served as Senior Vice president and Head of Cell Therapy Development and Operations at BMS from November 2019 until July 2021, as Executive Vice President of Cell Therapy Development and operations at Celgene Corporation since April 2018 until November 2019. She serves as Senior Vice President and Head of Cell Therapy Development & Operations at Bristol Myers Squibb. At BMS, Dr. Lee leads teams responsible for developing new cell therapy processes and technologies, manufacturing cell therapy products, designing new facilities and building the global supply chain to deliver these new medicines for patients. She serves as Director of the Alliance of Regenerative Medicine. She serves on the Board of Directors for American Institute of Chemical Engineers and JW Therapeutics. She served as Executive Vice President of Technical Operations at Juno Therapeutics, Inc. since November 27, 2017 until April 2018. Dr. Lee was responsible for process development, manufacturing, supply chain, quality assurance and end-to-end process and platform optimization for all aspects of Juno's engineered T cell product candidates. Prior to Juno, Dr. Lee joined Genentech in 2005. She served as Senior Vice President of Process Research and Development of Genentech, Inc. since 2005. She served as Global Head of Global Technical Development at RocheGenentech since 2009 until November 2009 and led a team of more than 2,500 professionals responsible for end-to-end chemistry, manufacturing and control (CMC) and technical support for all pipeline and commercial products. She was responsible for developing and delivering all clinical stage products in Roche’s global pipeline, as well as technology transfers and technical support for all commercial products. Earlier, she was at Merck & Co., where she led and developed new vaccines and technologies in R&D and then was responsible as VP for process engineering and technical operations at 10 chemical sites around the world. Over the course of her career, she has contributed to the development of hundreds of new investigational drugs and the licensure and commercialization of 25 new vaccines and medicines, with the most recent being two new CAR-T cell products for blood cancers. Dr. Lee served as Vice President of Process Research and Development of Genentech Inc. Dr. Lee served as Vice President of Process Development of Genentech, Inc. since January 9, 2006. She was responsible for the development, implementation and support of clinical and commercial production processes and technologies of Genentech, Inc. Dr. Lee worked at Merck & Company, where she served several senior leadership positions in vaccine development in the Merck Research Laboratories and served as its Vice President of Chemical Technology and Engineering in the manufacturing division. She directed the development, design and start-up of chemical manufacturing facilities and led supply chain optimization and process improvements for new and licensed products. Dr. Lee has authored over 40 scientific publications and holds several patents. She is a Member of the National Academy of Engineering, fellow of American Academy of Arts and Sciences, American Institute of Medical and Biological Engineering and Member of the Washington State Academy of Sciences. She holds a Bachelor of Science in Chemical Engineering from Cornell University. She also earned a Master of Science and Ph.D. in Biochemical Engineering with a concentration in molecular biophysics and biochemistry from Yale University.

Positions